Article Text

other Versions

Download PDFPDF
Interaction study between rtPA and bevacizumab
  1. Céline Faure1,
  2. Richard Macrez2,
  3. Denis Vivien2,
  4. José-Alain Sahel1,
  5. Sébastien Bonnel1
  1. 1Ophthalmology Service, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
  2. 2Center for Imaging Neurosciences and Applications to Pathologies, University of Caen Basse Normandie, Cyceron, Caen Cedex F-14074, Caen Cedex, France
  1. Correspondence to Dr Céline Faure, Fondation Ophtalmologique Adolphe de Rothschild, 25–29, rue Manin, 75019 Paris, France; celinefaureb{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article by Treumer et al in the January 2010 issue of the journal, regarding the dual action of subretinal injection of recombinant tissue plasminogen activator (rtPA) and bevacizumab associated with pneumatic displacement in treating submacular haemorrhage secondary to age-related macular degeneration.1 Injecting both bevacizumab and rtPA in subretinal,2 or in intravitreal use,3–5 serves the purpose of treating both the subretinal haemorrhage and neovascularisation.

However, rtPA is a serine protease with its catalytic …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; not externally peer reviewed.